BioElectronics and Electrome Initiate Commercial Rollout of Drug-Free Pain Relief Technology

BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, announced that its strategic distribution and licensing agreement with Electrome Corporation has officially entered the execution phase, with manufacturing now underway for the launch of its flagship pulsed shortwave therapy product as part of the Electrome PAINKILLER platform. The partnership aims to accelerate awareness and adoption of drug-free pain therapy technologies across North America.

Electrome is developing a comprehensive AI-native pain management platform that integrates advanced artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. The system is designed to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions. Under the agreement, Electrome will market and distribute BioElectronics’ FDA-cleared pulsed shortwave therapy products, including ActiPatch and other products in the BioElectronics portfolio.

“We are excited to officially begin the commercial phase of this relationship with Electrome,” said Kelly Whelan, President of BioElectronics Corporation. “The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth.”

Electrome’s planned rollout will focus heavily on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems designed to streamline the consumer purchasing experience while increasing awareness of non-drug pain management solutions. Ken Mayer, CEO of Electrome Corporation, stated: “This is an exciting moment for both organizations. We believe BioElectronics’ technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption.”

BioElectronics’ pulsed shortwave therapy technology provides drug-free, non-invasive pain relief through a wearable therapy platform cleared by the U.S. FDA for the adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures. Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.

The move comes as consumers increasingly seek alternatives to opioid-based painkillers, which have been linked to addiction and overdose. The non-pharmaceutical pain management market is growing rapidly, and the partnership between BioElectronics and Electrome aims to capture a significant share by leveraging AI-driven marketing and direct-to-consumer sales. Electrome’s platform, described as a ‘comprehensive AI-native pain management platform,’ is intended to use predictive analytics and automation to identify and engage potential customers, making it easier for them to access and purchase the ActiPatch device.

BioElectronics Corporation is a medical device company focused on the development and commercialization of advanced bioelectronic therapies utilizing pulsed shortwave therapy technology for pain management and recovery applications. Its product portfolio includes ActiPatch, RecoveryRx, and RecoveryRx Veterinary. Electrome Corporation is a technology-enabled healthcare commercialization company focused on leveraging AI-driven systems, digital marketing, and advanced ecommerce infrastructure to scale innovative healthcare and wellness products in the direct-to-consumer marketplace.

This announcement marks a significant step forward for both companies as they prepare to bring an FDA-cleared, drug-free pain relief technology to a broader audience through an AI-enhanced consumer campaign. The success of this rollout could have implications for the pain management industry, potentially offering a viable non-pharmaceutical alternative for millions of Americans suffering from musculoskeletal pain.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioElectronics and Electrome Initiate Commercial Rollout of Drug-Free Pain Relief Technology.

The post BioElectronics and Electrome Initiate Commercial Rollout of Drug-Free Pain Relief Technology appeared first on citybuzz.